OncoSec Medical Inc Share Price Nasdaq
Equities
US68234L2079
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 28.35M 2.36B |
---|---|---|---|---|---|
Net income 2021 | -45M -3.75B | Net income 2022 | -34M -2.84B | EV / Sales 2021 | - |
Net cash position 2021 | 33.63M 2.81B | Net cash position 2022 | 1.12M 93.84M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.59
x | P/E ratio 2022 |
-0.83
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.57% |
Managers | Title | Age | Since |
---|---|---|---|
David Canton
CTO | Chief Tech/Sci/R&D Officer | - | 01/14/01 |
Sandra Aung
PRN | Corporate Officer/Principal | - | 12/20/12 |
Bridget O'Keeffe
PRN | Corporate Officer/Principal | - | 18/21/18 |
1st Jan change | Capi. | |
---|---|---|
+2.47% | 42.75B | |
+48.09% | 41.61B | |
+12.25% | 41.34B | |
-12.36% | 26.59B | |
+8.09% | 25.49B | |
-22.81% | 18.12B | |
+30.83% | 12.24B | |
-1.85% | 11.76B | |
+7.95% | 11B |